Nexus Investment Management Inc. Acquires 450 Shares of Pfizer Inc. (NYSE:PFE)
Nexus Investment Management Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 0.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 683,345 shares of the biopharmaceutical company’s stock after purchasing an additional 450 shares during the period. Pfizer makes up about 3.5% of Nexus Investment Management Inc.’s holdings, making the stock its 12th biggest position. Nexus Investment Management Inc.’s holdings in Pfizer were worth $24,553,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of PFE. Nuveen Asset Management LLC increased its holdings in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after acquiring an additional 34,544,423 shares during the period. Natixis bought a new stake in Pfizer during the 2nd quarter worth approximately $258,466,000. Invesco Ltd. increased its holdings in Pfizer by 14.6% during the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock worth $914,857,000 after acquiring an additional 2,693,349 shares during the period. Thoroughbred Financial Services LLC increased its holdings in Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after acquiring an additional 2,596,269 shares during the period. Finally, Marshall Wace North America L.P. increased its holdings in Pfizer by 52.9% during the 1st quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock worth $315,635,000 after acquiring an additional 2,571,626 shares during the period. 71.69% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 target price on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley decreased their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Finally, DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a report on Wednesday, August 28th. Thirteen investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $45.25.
Shares of NYSE:PFE traded up $0.26 during trading on Wednesday, reaching $35.69. The company had a trading volume of 10,984,742 shares, compared to its average volume of 24,010,037. The company has a fifty day moving average of $35.92 and a two-hundred day moving average of $40.00. The stock has a market capitalization of $198.73 billion, a P/E ratio of 11.90, a price-to-earnings-growth ratio of 2.86 and a beta of 0.66. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.77 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 4.03%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What is included in the gross domestic product?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.